Gliknik commences dosing in Phase II oral cavity cancer trial

US-based biopharmaceutical firm Gliknik has commenced patient dosing in a Phase II clinical trial of immunomodulatory therapeutic biropepimut-S (GL-0817) to prevent recurrence of oral cavity squamous cell cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news